Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC)

7Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Lung cancer is one of the leading causes of tumor-related mortalities worldwide. NSCLC is the most common type of lung cancer. In recent years, advancements in chemoradiotherapy and immunotherapy have led to unprecedented survival benefits in some patients. However, conventional therapies such as radiation and chemotherapy are not effective in all patients due to the chemo or radioresistance mechanisms; as a result, there is an urgent need for understanding the resistant mechanism. Given that malignancies are caused by changes in cell homeostasis, autophagy may help chemo/radiosensitization by removing damaged compartments and enhancing tumor clearance. Autophagy, on the other hand, may help cancer cells survive by increasing the breakdown of cell cycle regulators. Considering these inconsistencies, this study aimed to overview the intricacy of autophagy in response to chemoradiotherapy in lung cancer.

Cite

CITATION STYLE

APA

Zadeh, F. A., Raji, A., Ali, S. A. J., Abdelbasset, W. K., Alekhina, N., Iswanto, A. H., … Jalil, A. T. (2022, May 1). Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC). Pathology Research and Practice. Elsevier GmbH. https://doi.org/10.1016/j.prp.2022.153823

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free